Pharmacogenomics of cancer chemotherapy-induced toxicity.
Pharmacogenomics is the study of inherited differences in interindividual drug disposition and effects. A major goal of this effort in cancer chemotherapy is the avoidance of severe, potentially life-threatening drug toxicity for patients. Genetic polymorphisms in drug-metabolizing enzymes and other molecules involved in drug disposition are responsible for much of the interindividual differences in the toxicity of many chemotherapy agents. This review will discuss clinically relevant examples of gene polymorphisms that influence toxicity and the experimental tools that have been utilized for discovering toxicity-related polymorphisms.
Miller
C Ryan
CR
Division of Neuropathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
McLeod
Howard L
HL
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control*; D014453:Glucuronosyltransferase / Q000235:genetics; D006801:Humans; D008780:Methyltransferases / Q000235:genetics; D009363:Neoplasm Proteins / Q000235:genetics; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D010597:Pharmacogenetics / Q000379:methods*; D011110:Polymorphism, Genetic
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D008780:Methyltransferases; D014453:Glucuronosyltransferase